The weight-loss version of Simvastatin has been approved for cardiovascular indications in China.

On December 22, Novo Nordisk announced that the application for the cardiovascular indications of the reduced version of semaglutide injection has been approved in China, and it is suitable for reducing the risk of major cardiovascular events in adults diagnosed with cardiovascular disease and a BMI of 27 or higher. According to the company, as one of the important means in the standardized treatment of obesity, the reduced version of semaglutide injection can achieve a weight loss of more than 20% in about one-third of patients and can reduce the risk of major adverse cardiovascular events by 20%. It is the only weight loss drug that has been proven to both reduce weight and reduce the risk of major adverse cardiovascular events.